COMMUNIQUÉS West-GlobeNewswire

Signati™ Medical, Inc. Announces Board Member Dr. Jones Joins Urology Austin
12/02/2024
Providence, RI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- LeRoy Jones, MD, Board-Certified Urologist and Signati™ Medical, Inc. Board Member, starts a new chapter in his career at Urology Austin. Dr. Jones has been on the [...]
Jaya Biosciences Presents Promising Preclinical Data in Alzheimer’s Disease at the 20th Annual WORLDSymposium™ 2024
12/02/2024
- Study results highlight potential utility of targeting lysosomal genes to treat neurodegenerative diseases, including Alzheimer’s - SOUTH SAN FRANCISCO, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc [...]
Accelus Strengthens Leadership with New Board Appointments
12/02/2024
Accelus CEO & Industry Veteran Kevin McGann and High-Performance Management Expert Bernie Haffey to Join as New Directors PALM BEACH GARDENS, Fla., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Accelus , a privately held [...]
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
12/02/2024
Advancements provide workflow efficiencies for NeuroStar® TMS providers MALVERN, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, [...]
Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer
12/02/2024
SAN CLEMENTE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
12/02/2024
Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus [...]
Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
12/02/2024
FDA grants orphan drug designation to Ruxoprubart (NM8074) for the treatment of PNH. Ruxoprubart is an Anti-Bb antibody that selectively blocks the alternative pathway while maintaining the intactness of the classical [...]
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
12/02/2024
FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company [...]
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
12/02/2024
Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor’s BVA-100 [...]
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
12/02/2024
TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated [...]
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
12/02/2024
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year [...]
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
12/02/2024
BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection testing at the Point-of-Care, announced a national distribution [...]
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
12/02/2024
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of [...]
Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego
12/02/2024
NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences. At BIO-Neuroscience, held in [...]
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
12/02/2024
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track [...]
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
12/02/2024
Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015 MDG1015 is a first-in-class, third generation TCR-T therapy targeting [...]
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
12/02/2024
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL ◊ AGILI-C ◊ Cartilage Repair Implant alongside the REGENETEN ◊ Bioinductive [...]
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
12/02/2024
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which NDA preparation is ongoing Investigator-Initiated OASIS Trial at UNC is a Phase 2 180-patient, [...]
Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
12/02/2024
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral [...]

Pages